Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonmyeloablative alternative donor transplants.

Leo Luznik1, Paul V O'Donnell, Ephraim J Fuchs

  • 1Divisions of Hematologic Malignancies and Immunology/Hematopoiesis, Johns Hopkins Oncology Center, Baltimore, Maryland, USA. luznile@jhmi.edu

Current Opinion in Oncology
|February 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Personalized Desensitization for Donor-Specific Anti-HLA Antibodies in Allogeneic Blood or Marrow Transplantation.

Transplantation and cellular therapy·2025
Same author

Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide.

Transplantation and cellular therapy·2025
Same author

Post-Transplant Cyclophosphamide Improves Survival in HLA-DPB1 Mismatched Unrelated Donor Allogeneic Transplantation.

Transplantation and cellular therapy·2025
Same author

C-C motif chemokine receptor-like 2 promotes the interferon-γ signaling response in myeloid neoplasms with erythroid differentiation and mutated <i>TP53</i>.

Haematologica·2025
Same author

Safe and Effective Addition of Ruxolitinib to Graft-versus-host Prophylaxis in Older Adults Undergoing Reduced-intensity Allogeneic Hematopoietic Cell Transplantation.

Transplantation and cellular therapy·2025
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Nonmyeloablative allogeneic stem cell transplantation offers a safer approach for patients. Utilizing alternative donors, like unrelated or partially mismatched ones, expands treatment options for those without a matched sibling.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Nonmyeloablative preparative regimens offer reduced toxicity for allogeneic hematopoietic stem cell transplantation (HSCT).
  • This approach holds promise for older patients and those with organ impairment, utilizing matched sibling donors.
  • A significant barrier is the lack of matched sibling donors for over 65% of patients.

Purpose of the Study:

  • To explore the feasibility and potential of using alternative donors in nonmyeloablative allogeneic HSCT.
  • To extend the benefits of allogeneic transplantation to a broader patient population.

Main Methods:

  • Focus on alternative donor sources, including genotypically matched unrelated donors and partially mismatched related donors.
  • Evaluation of early clinical results from studies employing these alternative donor strategies.

Related Experiment Videos

Main Results:

  • Early clinical data indicate the feasibility of using alternative donors in nonmyeloablative allogeneic HSCT.
  • This approach shows potential to overcome donor limitations.

Conclusions:

  • Alternative donors are a viable option for nonmyeloablative allogeneic HSCT.
  • Expanding donor options can significantly increase access to life-saving transplantation for patients in need.